**Patient Discharge Summary**

**Patient Information:**

* Name: John Doe
* Date of Birth: January 1, 1975
* Admit Date: March 10, 2023
* Discharge Date: March 20, 2023

**Clinical Summary:**

John Doe, a 48-year-old male, was admitted to the endocrinology unit on March 10, 2023, with symptoms of increased thirst and urination. Upon admission, he was found to have a fasting plasma glucose (FPG) level of 250 mg/dL and a glycosylated hemoglobin (HbA1C) level of 9.5%. These values confirmed the diagnosis of type 2 diabetes. A random glucose value of 220 mg/dL was also obtained during the admission.

**Diagnostic and Therapeutic Interventions:**

* Initial laboratory tests, including complete blood count, comprehensive metabolic panel, and lipid profile, revealed no significant abnormalities.
* The patient underwent a comprehensive foot examination, which showed no signs of neuropathy or ulcers.
* Funduscopic examination revealed no signs of diabetic retinopathy.
* Urine testing for albuminuria was negative, and serum creatinine was within normal limits.
* The patient was started on metformin 500 mg twice daily, and his HbA1C level was rechecked after 1 week, showing a decrease to 8.1%.
* Due to the patient's moderate obesity (BMI 32.5), a GLP-1 receptor agonist, semaglutide 2.4 mg once weekly, was added to his regimen.
* The patient was educated on the causes of diabetes, symptoms and signs of hypoglycemia and hyperglycemia, and diabetic complications.
* He was also instructed on adjusting insulin doses based on blood glucose levels and carbohydrate intake.
* Dietary recommendations focused on whole foods and high-quality carbohydrates, accommodating his comorbid condition of hypertension.
* The patient was advised to engage in at least 150 minutes of moderate-intensity aerobic exercise per week, with adjustments for hypoglycemia risk.

**Medications:**

* Metformin 500 mg twice daily
* Semaglutide 2.4 mg once weekly
* Aspirin 81 mg daily (for secondary prevention of cardiovascular disease)

**Discharge Instructions:**

1. Continue metformin and semaglutide as prescribed.
2. Monitor blood glucose levels regularly and adjust insulin doses as needed.
3. Engage in regular physical activity, incorporating both aerobic and resistance exercises.
4. Follow a balanced diet, focusing on whole foods and high-quality carbohydrates.
5. Attend regular follow-up appointments with your primary care physician and endocrinologist.
6. Schedule a follow-up appointment with the podiatrist for regular foot care.
7. Get vaccinated against Streptococcus pneumoniae, influenza virus, hepatitis B, varicella, and SARS-CoV-2.
8. Consider medical devices or surgical treatments for obesity if you are interested in weight loss.

**Follow-up Care:**

The patient will be followed up with in 4 weeks to monitor his blood glucose levels, HbA1C, and lipid profile. He will also be evaluated for any signs of diabetic complications or hypoglycemia.

**Conclusion:**

John Doe was diagnosed with type 2 diabetes during his hospital stay and was started on metformin and a GLP-1 receptor agonist. He was educated on the causes of diabetes, symptoms and signs of hypoglycemia and hyperglycemia, and diabetic complications. He was also provided with dietary recommendations and physical activity guidelines. The patient will require regular follow-up care to monitor his progress and adjust his treatment regimen as needed.